New appointment at Constellation Pharmaceuticals
This article was originally published in Scrip
Executive Summary
Constellation Pharmaceuticals, a US biopharmaceutical company discovering and developing drugs targeting epigenetic regulation of the human genome, has appointed Dr Mark Goldsmith chief executive officer and director. Dr Goldsmith was previously senior executive-in-residence at the healthcare venture capital firm Prospect Venture Partners. He has also served as co-founder and CEO of Cogentus Pharmaceuticals and senior vice-president of Genencor International.